Microglia, central nervous system (CNS) resident mononuclear phagocytes, are broadly distributed throughout the brain and spinal cord. They originate from yolk sac-derived progenitors and colonize the CNS rudiment, where they subsequently expand and differentiate (1, 2). Microglia constitute ∼10% of the cells in the CNS and play critical roles in immune surveillance and clearance of invading pathogens (3, 4). In addition, microglia influence synapse formation (5) and participate in neuronal network refinement through phagocytosis of less active presynaptic boutons (6, 7). During homeostasis, microglia clear the debris that results from neuronal cell loss and glial turnover. Microglia are activated in response to brain injury or disease and may offer therapeutic opportunities for a broad spectrum of CNS disorders, ranging from multiple sclerosis to Alzheimer's disease and autism (8-10). However, rigorous investigations into the role of microglia, and attempts to manipulate them for therapeutic purposes, have been limited by a lack of biomarkers to distinguish microglia from other closely related myeloid subsets. An ideal microglial marker would be selectively and stably expressed by all microglia, conserved across species, and localized to the cell surface to facilitate antibody-based cell sorting. The search may finally be over. In PNAS, Bennett et al. (11) identify transmembrane protein 119 (Tmem119) as a microglia-specific biomarker specific for mouse and human (Fig. 1) . The authors developed anti-Tmem119 mAbs suitable for cell sorting and immunohistological staining. Equipped with anti-Tmem119, they isolated (i) developing, (ii) resting, and (iii) activated microglia and performed deep RNA-sequencing. Data mining of microglia transcriptomes provides rich insights into gene expression, identifies many gene products associated with neurological disorders, and defines transcriptional changes as microglia mature or become "classically" activated. Importantly, Tmem119 immunoreactivity (IR) was carefully examined under various injury paradigms that trigger CNS infiltration by bone marrow (BM)-derived immune cells and found to be a stable marker selective for microglia.
The development of microglia-specific tools has been hampered by the close resemblance between microglia and their hematopoietic relatives, particularly monocyte-derived macrophages. Consequently, there is a high degree of overlap in expression of cell surface molecules. For example, CD11b, CD115, Iba-1, and F4/80 are common to monocytes/macrophages and microglia alike. The fractalkine receptor (CX3CR1) is strongly expressed by microglia but also by subsets of circulating monocytes that repopulate macrophage populations in noninflamed peripheral organs during homeostasis (12) . In fact, CX3CR1 expression defines the two major subsets of circulating monocytes in both humans and mice. Some investigators have found myeloid cells (presumably microglia) in the juxtavascular regions of the CNS parenchyma that express CD11c, a marker traditionally associated with dendritic cells (13) . CD11c
+ microglia would be difficult to distinguish from monocyte-derived dendritic cells that accumulate in the CNS during multiple sclerosis (14, 15) . To further complicate matters, microglia are "plastic" cells: they assume different states of activation with distinct gene-expression patterns, cell surface phenotypes, and functions (4). "Resting" microglia are stationary cells, constantly sampling the local microenvironment with their long and highly ramified extensions. They are unable to phagocytose debris and lack many surface receptors required for antigen presentation. In contrast, activated microglia are highly motile phagocytic cells that engage in antigen presentation and proinflammatory pathways (3). The expression of several markers that have been used to identify microglia changes with activation, obscuring their specificity in the setting of nervous system injury or disease. CD45 is expressed at low or intermediate levels on resting microglia, but is up-regulated with activation or aging. This makes activated microglia difficult to distinguish from BM-derived monocytes in the inflamed CNS, both of which are CD45 high . Expression levels of MHC class II and CD11b on microglia fluctuate in a similar manner (16) .
In their quest to find microglia-specific markers, Bennett et al. 
CD11b
+ CD45 lo-int cells by flow-cytometric analysis of CNS mononuclear cells (17) . However, all of those markers are also expressed by at least some subsets of hematopoietic myeloid cells. Is Tmem119 subject to the same limitations? Bennett et al. (11) conducted Tmem119 immunolabeling in three experimental paradigms known to trigger neuroinflammation, including (i) sciatic nerve injury, (ii) intraperitoneal lipopolysaccharide injection to activate parenchymal microglia, and (iii) optic nerve crush injury. The authors convincingly demonstrate that Tmem119 IR is restricted to microglia and not associated with BM-derived monocytes/ macrophages under any of those conditions. BM-derived phagocytes do not contribute to the pool of established microglia in the unperturbed CNS (18) . However, peripheral myeloid cell engraftment of the CNS does occur following insults that compromise the blood-brain barrier and alter the parenchymal milieu. Although this is most evident in the context of neuroinflammatory diseases, such as multiple sclerosis and infectious encephalomyelitis, monocytes can infiltrate the CNS in response to brain and spinal cord trauma, infectious encephalomyelitis, cerebrovascular ischemia, CNS malignancy, and neurodegenerative diseases, such as Alzheimer's and amytrophic lateral sclerosis (18) (19) (20) (21) (22) (23) . Unlike other tissue-resident macrophages, microglial precursors do not transition through a monocytic stage (24) . Mature microglia also differ from most macrophages (including perivascular macrophages in the CNS) in that they survive high-dose ionizing irradiation and constitute a self-renewing population that is independent of adult hematopoiesis in the steady state (25, 26) . These observations suggest that the CNS microenvironment provides signals that induce and sustain properties that are unique to microglia. To directly test whether the CNS microenvironment induces Tmem119 expression in BM-derived cells, chimeric mice were constructed by reconstituting lethally irradiated wild-type hosts with GFP + BM donor cells (11) . At 3 and 6 mo following irradiation and BM transplantation, a significant fraction of Iba1 + cells in the CNS were derived from GFP + donor cells, including numerous cells along blood vessels, meninges, and in the parenchyma. Strikingly, none of these GFP + cells stained positive for Tmem119, even several months following engraftment in the CNS (11) . Together, these studies show that Tmem119 is superior to currently used methods for microglia identification.
To better compare genetic profiles of microglia in the developing, mature, and inflamed brain, Bennet et al. (11) FACsorted CNS mononuclear cells using anti-Tmem119. Isolated cells were subjected to deep sequencing and comparative analysis of transcriptomes. The transcriptome of murine microglia isolated on
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postnatal day 14 resembled that of analogous cells isolated from the adult CNS, suggesting that microglia are fully mature by that age. Remarkably, a number of human disease-related genes were strongly enriched in microglia, providing a platform to investigate the potential role of microglia in disparate brain conditions, ranging from developmental and metabolic disorders to epilepsy, neurodegenerative diseases, and psychiatric disorders. Microglia become rapidly activated following stimulation via pattern-recognition receptors. "Classic" activation by peripheral injection of lipopolysaccharide into adult mice caused rapid induction of proinflammatory genes. However, Tmem119 IR expression remained stable, underscoring its suitability as a marker of microglia irrespective of activation state or alterations in the CNS microenvironment.
The literature on microglial phenotype and function has grown dramatically over the past 10 y (10, 27). Future research will be greatly aided by the discovery of Tmem119 as a stable and specific microglial marker. Hence, the development of cell typespecific gene knock-out, inducible gene knock-out, and transgenic mouse models using the Tmem119 promoter will allow researchers to assess the contribution of specific gene products to the function of microglia during homeostasis and in disease pathogenesis. The location of Tmem119 on the cell surface will facilitate microglial cell isolation from the healthy and diseased CNS tissue (human or experimental animal models), for in-depth studies of the transcriptome (coding and noncoding RNAs), proteome, epigenetic, and posttranslational modifications and functional properties. The data generated are expected to accelerate the identification of novel disease mechanisms and molecular targets for therapeutic interventions following CNS injury or disease.
A number of interesting questions arise from the Bennett et al. microglia participate in neural tissue repair and demonstrate immunoregulatory properties. Is Tmem119 IR altered during the polarization of microglia toward different functional lineages? All of these questions may soon be addressed by studies using Tmem119-specific antibodies as well as Tmem119 −/− mutant mice. In sum, Tmem119 provides the research community with much needed molecular handles to identify and manipulate microglia with great specificity in CNS health and disease.
